Comparing MACI and microfracture treatments for knee cartilage defects in teens
Official title: A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Run by Vericel Corporation · NCT03588975 · Data updated 2026-11-12
This study is testing whether a new cartilage treatment called MACI works better than a standard procedure called microfracture for knee problems in teens aged 10 to 17.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 10 Years to 17 Years |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Vericel Corporation Industry-sponsored |
| Locations | 15 sites (Palo Alto, California and 14 other locations) |
| Status | Recruiting |
| Started | October 24, 2018 |
| Main results expected | February 2030 |
| Study ends | February 2030 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT03588975 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adolescents aged 10 to 17 years with symptomatic cartilage or osteochondral defects of the knee that meet specific size and stability criteria.
✕Probably not a fit
Patients who have had recent knee surgery or those with certain types of cartilage defects that do not meet the study criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to evaluate the efficacy and safety of MACI® compared to arthroscopic microfracture in treating symptomatic articular chondral or osteochondral defects in patients aged 10 to 17 years. The study is a 2-year, multicenter, randomized, open-label trial involving 45 patients who will be assigned to receive either MACI or microfracture treatment. Patients will undergo a screening arthroscopy to assess eligibility and measure cartilage lesion size before randomization. Those in the MACI group will have their chondrocytes processed for implantation, while those in the microfracture group will undergo the procedure during the screening visit.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for knee cartilage defects in adolescents, potentially leading to improved joint function and reduced pain.
How similar studies have gone: Previous studies have shown promising results with similar cartilage repair techniques, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 10 to 17 years at the time of planned randomization * Symptomatic cartilage or osteochondral defects * One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture). 1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment. 2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol. * At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft. * Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments. * Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy. * Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment. * Written informed consent Exclusion Criteria: * Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy) * Previous investigational drug or device use within 3 months prior to Screening * Avascular necrosis of the target knee (other than potential OCD lesion to be treated) * Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate * ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion * Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary) * Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint * Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis) * Known history of septic arthritis in the index knee joint * Current malignancy or treatment for malignancy within the past 5 years * Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin * Females who are pregnant or lactating * Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to: * Any condition that has potential for negatively impacting intra or postoperative course * Conditions that limit compliance with rehabilitation program * Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function * Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study * Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance
Where it's running
-
Stanford University School of Medicine
Palo Alto, California, United States Recruiting -
Shriners Hospital for Children Northern California
Sacramento, California, United States Recruiting -
University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
Sacramento, California, United States Recruiting -
Ochsner Health System-Elmwood
New Orleans, Louisiana, United States Recruiting -
Johns Hopkins Hospital
Baltimore, Maryland, United States Recruiting -
University of Michigan Medsport Orthopaedic Surgery
Ann Arbor, Michigan, United States Recruiting
Show 9 more locations
-
Akron Children's Hospital
Akron, Ohio, United States Recruiting -
The Ohio State University Jameson Crane Sports Medicine Institute
Columbus, Ohio, United States Recruiting -
Penn Medicine University City
Philadelphia, Pennsylvania, United States Recruiting -
The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
Philadelphia, Pennsylvania, United States Recruiting -
University Orthopedics, Inc.
East Providence, Rhode Island, United States Recruiting -
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States Recruiting -
Montefiore Medical Center/Albert Einstein College of Medicine
The Bronx, New York, United States Completed -
Texas' Children Hospital
Houston, Texas, United States Completed -
Children's Medical Center Plano
Plano, Texas, United States Completed
Study contacts
- Study coordinator: Vericel Clinical Affairs
- Email: clinicalhotline@vcel.com
- Phone: 978-347-2876
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MACI versus bone marrow stimulation for symptomatic ankle cartilage defects in people 17–65
This treatment comparison tests whether MACI (your own cultured cartilage cells on a collagen membrane) works better than bone marrow stimulation for people aged 17 to 65 with symptomatic cartilage defects of the talus.
-
Using autologous chondrocyte suspension for knee cartilage repair
This study is testing whether using a patient’s own cartilage cells can help repair knee cartilage damage and improve their knee function over a year.
-
MaioRegen Prime for deep knee osteochondral lesions
This study tests MaioRegen Prime versus debridement to see if the scaffold helps knee cartilage repair in adults with deep osteochondral knee lesions.
-
Evaluating the outcomes of cartilage repair surgery in the knee
This study is testing how well cartilage repair surgery helps people with knee injuries feel and move better after the operation.
-
Effects of PRP, PPP, and BMAC on recovery after hip surgery for labral issues
This study is testing whether treatments like platelet-rich plasma and bone marrow concentrate can help people recover better after hip surgery for labral issues.
-
Using rib cartilage to treat ankle joint lesions
This study is testing whether using rib cartilage to treat ankle joint damage can help people recover better and have fewer side effects than a different treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.